Physician profile
Benjamin L Huff
NPI 1568774248
$9,458.26
in general payments reported to CMS, 2019-2025
47 companies · $57.11 in 2025
The $57.11 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,106 · 2020: $429 · 2021: $1,656 · 2022: $1,891 · 2023: $1,843 · 2024: $1,477 · 2025: $57.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,376.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,348.74 | 2019-2024 | |
| Glaxosmithkline, LLC. | $1,334.86 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $1,254.17 | 2021-2024 | |
| Novo Nordisk INC | $618.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $554.79 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $465.22 | 2019-2023 | Jardiance |
| Amgen INC. | $452.88 | 2019-2022 | |
| Abbott Laboratories | $406.70 | 2022-2024 | Freestyle Libre 3, Eterna |
| Janssen Pharmaceuticals, INC | $370.10 | 2019-2022 | |
| Amarin Pharma, INC. | $255.24 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $252.36 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $231.95 | 2019-2024 | Eliquis |
| Merck Sharp & Dohme LLC | $202.19 | 2019-2023 | Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.61 | 2019-2024 | Xifaxan |
| Daiichi Sankyo INC. | $151.69 | 2019-2024 | Injectafer |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $98.26 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $97.31 | 2021-2025 | Farxiga, Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $96.95 | 2022 | |
| Astellas Pharma US INC | $87.18 | 2019-2023 | Veozah, Myrbetriq |
| Allergan, INC. | $84.94 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.23 | 2019-2022 | |
| Eisai INC. | $76.14 | 2020-2021 | |
| Boston Scientific Corporation | $58.03 | 2023 | Wavewriter Alpha Prime 16 |
| Kowa Pharmaceuticals America, INC. | $54.35 | 2020-2022 | |
| Genentech USA, INC. | $53.94 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $49.31 | 2019 | |
| Inspire Medical Systems, INC. | $45.64 | 2023 | Inspire |
| Dexcom, INC. | $45.32 | 2023-2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $44.40 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $41.37 | 2023 | Rexulti |
| Philips North America LLC | $38.33 | 2023-2024 | (Ck7) Extended Holter |
| Dynavax Technologies Corporation | $36.36 | 2024 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $35.76 | 2021-2022 | |
| Nevro Corp. | $30.37 | 2022-2023 | Senza |
| Resmed Corp | $22.50 | 2019 | |
| Inogen, INC. | $20.55 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Jazz Pharmaceuticals INC. | $20.22 | 2021 | |
| Lundbeck LLC | $20.05 | 2023 | Vyepti |
| Xeris Pharmaceuticals, INC. | $19.48 | 2023 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $15.37 | 2024 | Auvelity |
| Gilead Sciences, INC. | $15.33 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.22 | 2022 | |
| Sanofi Pasteur INC. | $14.96 | 2019 | |
| Exact Sciences Corporation | $13.73 | 2024 | Cologuard Collection Kit |
| Baxter Healthcare | $13.49 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Bardy Diagnostics, INC. | $9.00 | 2020 | |
| Sumitomo Pharma America, INC. | $8.54 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Huff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.